ABSTRACT
CONTEXT: Paragangliomas and pheochromocytomas (PPGLs) exhibit variable malignancy, which is difficult to determine by histopathology, amine measurements or tissue genetic analyses. OBJECTIVE: To evaluate whether a 51-neuroendocrine gene blood analysis has clinical utility as a diagnostic and prognostic marker. DESIGN: Prospective cohort study. Well-differentiated PPGLs (n = 32), metastatic (n = 4); SDHx mutation (n = 25); 12 biochemically active, Lanreotide treated (n = 4). Nine patients had multiple sampling. Age- and gender-matched controls and GEP-NETs (comparators). METHODS: Circulating neuroendocrine tumor mRNA measured (qPCR) with multianalyte algorithmic analysis. Metabolic, epigenomic and proliferative genes as well as somatostatin receptor expression were assessed (averaged, normalized gene expression: mean ± s.e.m.). Amines were measured by HPLC and chromogranin A by ELISA. Analyses (2-tailed): Fisher's test, non-parametric (Mann-Whitney), receiver-operator curve (ROC) and multivariate analysis (MVA). All data are presented as mean ± s.e.m. RESULTS: PPGL were NETest positive (100%). All exhibited higher scores than controls (55 ± 5% vs 8 ± 1%, P = 0.0001), similar to GEP-NETs (47 ± 5%). ROC analysis area under curve was 0.98 for differentiating PPGLs/controls (cut-off for normal: 26.7%). Mutation status was not directly linked to NETest. Genetic and molecular clustering was associated (P < 0.04) with NETest scores. Metastatic (80 ± 9%) and multicentric (64 ± 9%) disease had significantly (P < 0.04) higher scores than localized disease (43 ± 7%). Progressive disease (PD) had the highest scores (86 ± 2%) vs stable (SD, 41 ± 2%) (P < 0.0001). The area under the curve for PD from SD was 0.93 (cut-off for PD: 53%). Proliferation, epigenetic and somatostatin receptor gene expression was elevated (P < 0.03) in PD. Metabolic gene expression was decreased in SDHx mutations. Repeat NETest measurements defined clinical status in the 9 patients (6 SD and 3 PD). Amine measurement was non-informative. Multivariate analysis identified NETest >53% as an independent prognostic factor. CONCLUSION: Circulating NET transcript analysis is positive (100% diagnostic) in well-differentiated PCC/PGL, scores were elevated in progressive disease irrespective of mutation or biochemical activity and elevated levels were prognostic.
Subject(s)
Paraganglioma/genetics , Pheochromocytoma/genetics , Adolescent , Adult , Biomarkers, Tumor/genetics , Child , Female , Humans , Middle Aged , Neuroendocrine Tumors/genetics , Pregnancy , Prospective Studies , Receptors, Somatostatin/metabolism , Young AdultABSTRACT
After the first cases of primary aldosteronism were described and characterized by Conn, a substantial body of experimental and clinical evidence about the long-term effects of excess aldosterone on the cardiovascular system was gathered over the last 5 decades. The prevalence of primary aldosteronism varies considerably between different studies among hypertensive patients, depending on patient selection, the used diagnostic methods, and the severity of hypertension. Prevalence rates vary from 4.6 to 16.6% in those studies in which confirmatory tests to diagnose primary aldosteronism were used. There is also growing evidence indicating that prolonged exposure to elevated aldosterone concentrations is associated with target organ damage in the heart, kidney, and arterial wall, and high cardiovascular risk in patients with primary aldosteronism. Therefore, the aim of treatment should not be confined to BP normalization and hypokalemia correction, but rather should focus on restoring the deleterious effects of excess aldosterone on the cardiovascular system. Current evidence convincingly demonstrates that both surgical and medical treatment strategies beneficially affect cardiovascular outcomes and mortality in the long term. Further studies can be expected to provide better insight into the relationship between cardiovascular risk and complications and the genetic background of primary aldosteronism.
Subject(s)
Cardiovascular Diseases/etiology , Hyperaldosteronism/complications , Blood Pressure , Cardiovascular Diseases/physiopathology , Humans , Hyperaldosteronism/epidemiology , Hyperaldosteronism/physiopathology , Organ Specificity , Prevalence , Risk FactorsABSTRACT
Recent studies indicate that resistant hypertension (RHTN) is present in about 12% of the treated hypertensive population. However, patients with true RHTN (confirmed out of the office) have not been widely studied. We prospectively studied 204 patients (123 male, 81 female, mean age 48.4 years, range 19-65 years) with truly RHTN (ambulatory daytime mean blood pressure >135/85 mm Hg). We evaluated the frequency of obstructive sleep apnea (OSA), renal artery stenosis (RAS), primary aldosteronism (PA) and other secondary forms of hypertension (HTN) and conditions. Mild, moderate and severe OSA were present in 55 (27.0%), 38 (18.6%) and 54 (26.5%) patients, respectively. Secondary forms of HTN were diagnosed in 49 patients (24.0%), the most frequent being PA (15.7%) and RAS (5.4%). Metabolic syndrome (MS) was present in 65.7% of patients. Excessive sodium excretion was evident in 33.3% of patients and depression in 36.8% patients. In patients with RHTN, OSA and MS were the most frequent conditions, frequently overlapping with each other and also with PA. Our data indicate that in the vast majority of patients with truly RHTN, at least one of three co-morbidities-OSA, MS and PA-is present. Other conditions, even though less frequent, should also be taken into the consideration.
Subject(s)
Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Drug Resistance , Hypertension/drug therapy , Hypertension/epidemiology , Adult , Aged , Comorbidity , Depression/diagnosis , Depression/epidemiology , Female , Humans , Hyperaldosteronism/diagnosis , Hyperaldosteronism/epidemiology , Hypertension/diagnosis , Hypertension/physiopathology , Male , Metabolic Syndrome/diagnosis , Metabolic Syndrome/epidemiology , Middle Aged , Poland/epidemiology , Prevalence , Prospective Studies , Renal Artery Obstruction/diagnosis , Renal Artery Obstruction/epidemiology , Risk Factors , Severity of Illness Index , Sleep Apnea, Obstructive/diagnosis , Sleep Apnea, Obstructive/epidemiology , Treatment Failure , Young AdultABSTRACT
Two major categories of mortality are distinguished in patients with phaeochromocytoma. First, the effects of excessive circulating catecholamines may result in lethal complications if the disease is not diagnosed and/or treated timely. The second category of mortality is related to development of metastatic disease or other neoplasms. Improvements in disease recognition and diagnosis over the past few decades have reduced mortality from undiagnosed tumours. Nevertheless, many tumours remain unrecognised until they cause severe complications. Death resulting from unrecognised or untreated tumour is caused by cardiovascular complications. There are also numerous drugs and diagnostic or therapeutic manipulations that can cause fatal complications in patients with phaeochromocytoma. Previously it has been reported that operative mortality was as high as 50% in unprepared patients with phaeochromocytoma who were operated and in whom the diagnosis was unsuspected. Today mortality during surgery in medically prepared patients with the tumour is minimal. Phaeochromocytomas may be malignant at presentation or metastases may develop later, but both scenarios are associated with a potentially lethal outcome. Patients with phaeochromocytoma run an increased risk to develop other tumours, resulting in an increased mortality risk compared to the general population. Phaeochromocytoma during pregnancy represents a condition with potentially high maternal and foetal mortality. However, today phaeochromocytoma in pregnancy is recognised earlier and in conjunction with improved medical management, maternal mortality has decreased to less than 5%.
Subject(s)
Adrenal Gland Neoplasms/mortality , Pheochromocytoma/mortality , Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/physiopathology , Cardiovascular Diseases/etiology , Cardiovascular Diseases/mortality , Catecholamines/blood , Female , Fetal Mortality , Humans , Male , Maternal Mortality , Pheochromocytoma/blood , Pheochromocytoma/physiopathology , Pheochromocytoma/secondary , Pregnancy , Pregnancy Complications, Neoplastic/blood , Pregnancy Complications, Neoplastic/mortality , Pregnancy Complications, Neoplastic/physiopathologyABSTRACT
Patients with pheochromocytoma or paraganglioma are at risk of developing tumor recurrences or new tumors after successful resection of the primary tumor. This review summarizes current knowledge concerning the incidence and risk factors for such events. The overall incidence exceeds 15%. Patients with inherited tumors have a higher probability of recurrence or new tumors. Most recurrences are metastatic, particularly in patients with SDHB mutations or nonhereditary tumors. We recommend the determination of plasma or urinary metanephrines (normetanephrine and metanephrine) 1 month after surgery. In patients with sporadic, single tumors ≤5 cm in diameter, clinical and biochemical follow-up should be performed every 2 years. However, this follow-up period can be reduced to yearly, if it is more simple and more convenient for patients and physicians. Patients with larger or multiple but apparently benign tumors and/or inherited disease should be tested 6 months after surgery and then every year for the rest of their lives. Imaging follow-up is also required in patients with inherited or malignant tumors.
Subject(s)
Adrenal Gland Neoplasms/surgery , Pheochromocytoma/surgery , Postoperative Care , Postoperative Complications/epidemiology , Adrenal Gland Neoplasms/nursing , Adrenal Gland Neoplasms/pathology , Follow-Up Studies , Humans , Metanephrine/blood , Paraganglioma/nursing , Paraganglioma/pathology , Paraganglioma/surgery , Pheochromocytoma/nursing , Pheochromocytoma/pathology , Postoperative Complications/blood , Postoperative Complications/etiologyABSTRACT
We report a case of a 53-year-old hypertensive male with takotsubo cardiomyopathy in the setting of pheochromocytoma. Pheochromocytoma presenting as takotsubo cardiomyopathy is a recognized but uncommon occurrence with recently increasing number of published cases. We present typical apical ballooning syndrome, with transient left ventricular apical ballooning in contrast to several reports, in which patients with pheochromocytoma-induced cardiomyopathy had so called 'inverted'takotsubo cardiomyopathy. In patients being diagnosed with acute coronary syndrome symptoms without coronary artery stenosis or spasm, and pronounced blood pressure variability, pheochromocytoma-induced takotsubo or 'inverted' takotsubo cardiomyopathy should be kept in mind.
Subject(s)
Adrenal Gland Neoplasms/complications , Pheochromocytoma/complications , Takotsubo Cardiomyopathy/etiology , Adrenal Gland Neoplasms/diagnostic imaging , Adrenal Gland Neoplasms/physiopathology , Echocardiography , Humans , Hypertension/physiopathology , Hypertrophy, Left Ventricular/diagnostic imaging , Male , Middle Aged , Pheochromocytoma/diagnostic imaging , Pheochromocytoma/physiopathology , Takotsubo Cardiomyopathy/diagnostic imaging , Takotsubo Cardiomyopathy/physiopathology , Tomography, X-Ray Computed , Ventricular Dysfunction, Left/diagnostic imagingABSTRACT
We are presenting clinical characteristics, management and follow-up of five consecutive patients with renal artery aneurysm. Renal artery aneurysms are relatively uncommon, they rarely give rise to clinical manifestations and they are usually found incidentally. However with the introduction of Doppler ultrasound, computed tomography (CT) and magnetic resonance (MR) imaging, the diagnosis of renal artery aneurysms became more frequent.
Subject(s)
Aneurysm , Renal Artery , Adult , Aneurysm/diagnosis , Aneurysm/therapy , Female , Humans , Male , Middle AgedABSTRACT
Arteriovenous fistulas of the kidney are rare. They may be acquired, idiopathic or arise in congenital arteriovenous malformations. There are only few reports in the current literature describing the successful embolisation of idiopathic arteriovenous fistulas. We report a 47-year-old hypertensive female patient with a successfully embolised arteriovenous fistula. Diagnosis was made on the basis of colour duplex Doppler examination and this method enabled further successful embolisation of the fistula.
Subject(s)
Arteriovenous Fistula/therapy , Kidney/blood supply , Arteriovenous Fistula/complications , Embolization, Therapeutic , Female , Humans , Hypertension/complications , Hypertension/therapy , Kidney/diagnostic imaging , Middle Aged , Renal Artery/abnormalities , Renal Artery/diagnostic imaging , Renal Artery/surgery , Renal Veins/abnormalities , Renal Veins/diagnostic imaging , Renal Veins/surgery , Ultrasonography, Doppler, ColorABSTRACT
Pheochromocytoma, a potentially life-threatening disease, is a rare cause of hypertension. Most pheochromocytomas secrete excessive amounts of noradrenaline and adrenaline. It has been suggested by some authors that high circulating levels of dopamine and the catecholamine precursor dihydroxyphenylalanine (dopa) are more often associated with malignant rather than benign pheochromocytomas. Therefore the aim of this study was to evaluate urinary excretion of dopamine and dopa in patients with pheochromocytoma and to determine their role as a potential marker for malignancy of the tumour. We retrospectively analysed 120 consecutive patients (mean age 41 +/- 12 years) with histopathologically confirmed pheochromocytomas. All subjects were divided as follows: group 1 included patients with both elevated and normal dopamine urinary excretion; group 2 was characterized by increased and normal dopa urinary excretion. Dopamine urinary excretion was increased in all patients with malignant pheochromocytoma, but higher levels were also observed in some patients with a benign tumour included in group 1. Urinary excretion of dopa was in the normal range in all subjects with malignant pheochromocytoma. The results indicate that in some pheochromocytoma patients excessive dopamine excretion may point to malignant tumour, but is not a discriminating marker for malignancy in the whole studied group.